Diazepam versus alprazolam for the treatment of panic disorder

Journal of Clinical Psychiatry

Volumn 57, Issue 8, 1996, Pages 349-355

  Noyes Jr , Russell ^a   Burrows, Graham D ^b   Reich, James H ^c   Judd, Fiona K ^b   Garvey, Michael J ^a   Norman, Trevor R ^b   Cook, Brian L ^a   Marriott, Peter ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST MARY S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; DIAZEPAM; LORAZEPAM;

ADULT; AGORAPHOBIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PANIC; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SEDATION;

ADULT; AGE OF ONSET; ALPRAZOLAM; DIAZEPAM; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; PANIC DISORDER; PERSONALITY INVENTORY; PLACEBOS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 9444297271     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association; 1980
2. Ballenger JC. Efficacy of benzodiazepines in panic disorder and agoraphobia. J Psychiatr Res 1990;24(suppl 2):15-25
3. Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry 1962;119:432-438
4. Klein DF. Delineation of two drug-response anxiety syndromes. Psychopharmacologia 1964;5:397-408
5. Chouinard G, Annable L, Fontaine R, et al. Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. Psychopharmacology (Berl) 1982;77:229-233
6. Ballenger JC, Burrows G, DuPont R, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413-422
7. Cross-National Collaborative Panic Study. Drug treatment of panic disorder. Br J Psychiatry 1992;160:191-202
8. Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69-76
9. Noyes R, Anderson DJ, Clancy J, et al. Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 1984;41:287-292
10. Dunner DL, Ishiki D, Avery DH, et al. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986;47:458-460
11. Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989;50: 418-423
12. Schweizer E, Pohl R, Balon R, et al. Lorazepam vs alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990;23:90-93
13. Noyes R, Garvey MJ, Cook BL. Benzodiazepines other than alprazolam in the treatment of panic disorder. In: Ballenger JC, ed. Clinical Aspects of Panic Disorder. New York, NY: Wiley-Liss; 1990:251-258
14. Bradwein J. Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions. Can J Psychiatry 1993;38(4, suppl):S109-S113
15. Herman JB, Brotman AW, Rosenbaum JF. Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. J Clin Psychiatry 1987;48(10, suppl):22-26
16. Spitzer RL, Williams JB. Structured Clinical Interview for DSM-III. New York, NY: New York State Psychiatric Institute; 1983
17. Sheehan DV. The Anxiety Disease. Rev ed. New York, NY: Bantam Books; 1986
18. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
19. Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther 1979;17:263-267
20. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego, Calif: Educational and Industrial Testing Service; 1971
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
22. Marks IM, Gelder MG. A controlled retrospective study of behaviour therapy in phobic patients. Br J Psychiatry 1965;111:561-573
23. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986;22: 343-381
24. Woodman CL, Noyes R, Ballenger JC, et al. Predictors of response to alprazolam and placebo in patients with panic disorder. J Affect Disord 1994;30:5-13
25. Bystritsky A, Waikar S. Inert placebo versus active medication: patient blind ability in clinical pharmacological trials. J Nerv Ment Dis 1994;182: 485-487
26. Klerman GL. Drug treatment of panic disorder. Br J Psychiatry 1992;161: 465-471
27. Clark DB, Taylor CB, Roth WT, et al. Surreptitious drug use by patients in a panic disorder study. Am J Psychiatry 1990;147:507-509
28. Maier W, Roth M, Argyle N, et al. Avoidance behavior: a predictor of the efficacy of pharmacotherapy in panic disorder. Eur Arch Psychiatry Clin Neurosci 1991;241:151-158
29. Pollack MH, Otto MW, Sacks GS, et al. Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. J Affect Disord 1994;30:273-281
30. Uhlenhuth EH, Matuzas W, Glass RM, et al. Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989;17:261-270
31. Noyes R, DuPont RL, Pecknold JC, et al. Alprazolam in panic disorder and agoraphobia: results of a multicenter trial, II: patient acceptance, side effects and safety. Arch Gen Psychiatry 1988;45:423-428
32. Noyes R, Garvey M, Cook B, et al. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am J Psychiatry 1991; 148:517-523
33. Ballenger JC, Peeknold J, Rickels K, et al. Medication discontinuation in panic disorder. J Clin Psychiatry 1993;54(10, suppl):15-21
34. Abelson JL, Curtis GC. Discontinuation of alprazolam after successful treatment of panic disorder: a naturalistic follow-up study. Journal of Anxiety Disorders 1993;7:107-117
35. Schweizer E, Rickels K, Case G, et al. Long-term therapeutic use of benzodiazepines, II: effects of gradual taper. Arch Gen Psychiatry 1990;47: 908-915
36. Noyes R Jr, Garvey MJ, Cook BL, et al. Benzodiazepine withdrawal: a review of the evidence. J Clin Psychiatry 1988;49:382-389
37. Rosenberg R, Bech P, Mellergård M, et al. Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. Acta Psychiatr Scand 1991;83(suppl 365):46-52
38. Basoglu M, Marks IM, Swinson RP, et al. Pretreatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure. J Affect Disord 1994;30:123-132
39. Noyes R, Holt C, Woodman C. Natural course of anxiety disorders. In: Mavissakalian M, Prien RF, eds. Long-Term Treatments of Anxiety Disorders. Washington, DC: American Psychiatric Press; 1996
40. Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986;47:580-586
41. Lepola U, Heikkinen H, Rimon R, et al. Clinical evaluation of alprazolam in patients with panic disorder: a double-blind comparison with imipramine. Hum Psychopharmacol 1990;5:159-164
42. Sellers EM, Ciraulo DA, DuPont RL, et al. Alprazolam and benzodiazepine dependence. J Clin Psychiatry 1993;54(10, suppl):64-75
43. Uhlenhuth EH, DeWit H, Balter MB, et al. Risk and benefits of long-term benzodiazepine use. J Clin Psychopharmacol 1988;8:161-167